Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer

Breast

Volumn 17, Issue 1, 2008, Pages 36-41

  Favier, Laure ^a   Isambert, Nicolas ^a   Zanetta, Sylvie ^a   Ferrant, Emmanuelle ^a   Mayer, Françoise ^a   Chauffert, Bruno ^a   Fumoleau, Pierre ^a   Garnier, Jérome ^b   Biville, Fabienne ^c   Coudert, Bruno ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b Laboratoires Roche   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Capecitabine; Chemotherapy; Metastatic breast cancer; Phase I trial; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; FLUOROURACIL; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER RADIOTHERAPY; CHOLESTASIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIVER FUNCTION TEST; MASTECTOMY; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 38949155306     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.06.003     Document Type: Article

References (25)

1. Carlson R.W., Edge S.B., and Theriault R.L. NCCN: Breast cancer. Cancer Control 8 (2001) 54-61
2. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
3. Fumoleau P., Delgado F.M., Delozier T., et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11 (1993) 1245-1252
4. Dieras V., Extra J.M., Bellissant E., et al. Efficacy and tolerance of vinorelbine and fluorouracile combination as first line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14 (1996) 3097-3104
5. Nolè F., de Braud F., Aapro M., et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 8 (1997) 865-870
6. Berruti A., Sperone P., Bottini A., et al. Phase II Study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 18 (2000) 3370-3377
7. Hochster H.S., Vogel C.L., Burman S.L., et al. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study. Oncologist 6 (2001) 269-277
8. Pienkowski T., and Jagiello-Gruszfeld A. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Int J Clin Pharmacol Res 21 (2001) 111-117
9. Zambelli A., Robustelli della Cuna F.S., Ponchio L., et al. Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 61 (2000) 241-247
10. Zambetti M., Mariani G., Demicheli R., et al. Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. Breast Cancer Res Treat 62 (2000) 135-139
11. Fumoleau P., Largillier R., Clippe C., et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40 (2004) 536-542
12. Jones L, Hawkins N, Westwood M., et al. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. Health Technol Assess 2004; 8: iii, xiii-143.
13. Lee S.H., Lee J., Park J., et al. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 21 (2004) 223-231
14. Leonard R.C., Twelves C., Breddy J., et al. Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience. Eur J Cancer 38 (2002) 2020-2024
15. Estevez LG, Batista N, Sanchez-Rovira P, et al. Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. In: Proceedings of the annual meeting of the american society of clinical oncology, vol. 23. p. 63, ASCO 40th meeting, June 5-8, 2004 New Orleans, LA, USA, June 5, 2004.
16. Ghosn M., Kattan J., Farhat F., et al. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26 (2006) 2451-2456
17. Hess D., Thurlimann B., Pagani O., et al. Capecitabine and vinorelbine in elderly patients (>= 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/29). Ann Oncol 15 (2004) 1760-1765
18. Lorusso V., Crucitta E., Silvestris N., et al. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer 4 (2003) 138-141
19. Stuart N, Bishop JL, Johnson SRD, et al. Vinorelbine and capecitabine (VX) for advanced breast cancer-a phase II study showing good activity and potential for further development. In: Proceedings of the annual meeting of the American society of clinical oncology vol. 22. p. 46, ASCO 39th meeting, May 31-June 3, 2003 Chicago, Il, USA, May 31, 2005.
20. Welt A., von Minckwitz G., Oberhoff C., et al. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16 (2005) 64-69
21. Xu B, Tian L, Wu Q, et al. Capecitabine (X) combined with vinorelbine (V) in Chinese patients (pts) with metastatic breast cancer (MBC). In: Proceedings of the annual meeting of the American society of clinical oncology vol. 23: 61, ASCO 40th meeting, June 5-8, 2004 New Orleans, LA, USA, June 5, 2005.
22. Nole F., Catania C., Munzone E., et al. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 6 (2006) 518-524
23. Delcambre C, Bourgois H, Veyret C, et al. A phase I/II study of capecitabine (X) combined with oral vinorelbine (V) as first or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC). Breast Cancer Res Treat 2004; 88: S68 [SABCS 2004, San Antonio, USA].
24. Nole F., Catania C., Sanna G., et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17 (2006) 322-329
25. Lorusso V., Spada M., Giampaglia M., et al. Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 17 (2006) vii15-vii17